Ligand Pharmaceuticals Incorporated LGND announced that its partner Prism Pharmaceuticals has entered into a definitive agreement to be acquired by Baxter International Inc. BAX. Prism Pharmaceuticals recently received FDA approval for Nexterone®, an antiarrhythmic agent which Ligand originally developed with its patented Captisol® formulation technology and licensed to Prism in 2006. Ligand is eligible to receive milestones, royalties and Captisol material sales revenue from this partnership.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in